Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
LaggingWe are a biotechnology company committed to the development of first-in-class and best-in-class targeted oncology therapies. Our goal is to establish a broad portfolio of differentiated clinical assets to improve the lives of cancer patients. Key to that strategy is our deep expertise in the discovery, design, development, manufacturing, and ultimately commercialization of antibody-drug conjugates and other oncology therapeutics.
In the company’s own words · 10-K filed Mar 3, 2026 · SEC EDGAR
Immunome, Inc. (IMNM) reported revenue of $5.5M in Q1 2026 (quarter ended March 31, 2026), up 88% from the same quarter a year earlier. That came with net loss of $54M. For the full year FY2025, revenue was $6.9M (−23% year on year) and net income −$212M.
Raw charts
8 series · TTMAs reported to the SEC, without any scoring.